Skip to content

Local Compression Seroma DIminution Objective (CLODIS)

Interest of Local Compression by Thoracic Bandage on the Management of Seroma in Patients Treated by Mastectomy With or Without Lymphadenectomy. Local Compression Seroma DIminution Objective

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03598712
Acronym
CLODIS
Enrollment
60
Registered
2018-07-26
Start date
2018-11-18
Completion date
2020-08-30
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Mastectomy, Seroma

Brief summary

This study evaluates the impact of local compression by chest bandage on the number of seroma punctures in patients treated by mastectomy with or without lymphadectomy. Half of the participants will have local compression by chest bandage in addition to seroma punctures while the other half will only have punctures.

Detailed description

The most common complication induced by mastectomy is seroma formation. This seroma is a serolymphatic effusion that is created in the days following surgery. Iterative puncture is the only treatment for seroma mentioned in the literature. A retrospective study in the investigator's establishment on 1800 patients determined that a second puncture greater than 250ml is predictive of a chronicisation of punctures. The research hypothesis is that by applying local compression by chest bandaging with the Urgo® K2 kit, the dead space created by surgery would be removed. This would help resorb the seroma and reduce the number of punctures.

Interventions

DEVICECompression by chest bandage urgo K2®

1. \- Installation of a short stretch belt (urgo K2® kit) 2. \- Installation of a long stretch cohesive band providing additional pressure necessary to reach therapeutic pressure and maintain the device (urgo K2® kit). 3. \- Control of the pressure exerted by the bandage by the KIKUHIME® Sub Bandge pressure Monitor device

PROCEDUREpunctures

Every 7 days after the second puncture of a volume \> 250ml of seroma, the patients are examined by 2 practitioners. They define the indication of the puncture. The seroma is aspirated after a skin puncture with a needle connected with a Redon® drain.

Sponsors

Centre Francois Baclesse
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Phase 3 prospective, randomized, monocentric controlled study

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient followed for histologically proven breast cancer treated by total mastectomy, whether or not dissociated from the sentinel node technique, with or without axillary curing. * Patient with a second seroma puncture with a volume greater than or equal to 250 ml. * Neo adjuvant chemotherapy authorized. * Absence of known metastases. * Patient has given written consent.

Exclusion criteria

* Mastectomy with immediate reconstruction. * Partial mastectomy. * Concurrent bilateral mastectomy. * Delay in healing observed at inclusion. * Patient under legal protection. * Chronic respiratory failure. * Patient with a pacemaker. * Personality disorders and known progressive psychiatric pathology. * Inability to submit to trial follow-up

Design outcomes

Primary

MeasureTime frameDescription
Number of puncture(s) after inclusion in both patient groups180 daysIn each group, we will count the number of punctures performed after the 2nd puncture with a volume \> 250ml (inclusion).

Secondary

MeasureTime frameDescription
comparison of the average change Pain scores between each arm180 days1. Numerical rating scale for pain (EN) The EN evaluates levels of pain intensity using an 10-point scale (range 0-10), with 0 being classified as no sensation, 3 pain threshold, 10 pain as bad as could be.(at each visit), 2. Neuropathic Pain (DN4) (inclusion and study exit)
The time required to take charge of adjuvant treatments180 daysDeferral of adjuvant therapy related to seroma: Treatment regimen and adjuvant appointments will be collected at inclusion. Each deviation will be analyzed and attributed or not to the presence or complications of seroma.
Volume punctured after inclusion in both patient groups.180 daysFor each new puncture, the volume of serolymphatic fluid will be measured and the time between two punctures analyzed
comparison of the average change anxiety scores between each arm180 daysAnxiety / depressions are assessed by the Hospital Anxiety and Depression scale (study inclusion and exit)
The aesthetic impact on the puncture site.180 daysThe evaluation of the aesthetic impact on the puncture zone will be carried out by comparing the photographs taken at the inclusion, during the visit to the consultation at 10-15 days after the last puncture (for the standard arm) and at 10-15 days after the removal of the bandage device and finally during the consultation with the oncologist.
Validation of a score allowing the description of the seroma of grades 2 and the indication of a puncture180 daysBased on the observation grids carried out by the 2 professionals during a separate evaluation, we compare the 4 items defined to the indication chosen for the puncture as well as the volume of puncture when it is carried out.
comparison of the average change Quality of life scores between each arm180 daysQuality of life is assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, for the cancer in general and EORTC QLQ-BR23 specifically for the breast cancer (study inclusion and exit). The EORTC QLQ-C30 questionnaire, resulting in a score for the quality of life between 0 to 100.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026